Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluzone High-Dose Quadrivalent + mRNA-1273
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to the concomitant administration of Fluzone High-Dose Quadrivalent (Sanofi Pasteur) and the Moderna COVID-19 vaccine (mRNA-1273). Fluzone High-Dose Quadrivalent is an inactivated influenza vaccine containing 60 μg of hemagglutinin per strain (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata), designed for superior protection in adults aged 65 and older. mRNA-1273 is a nucleoside-modified messenger RNA vaccine encapsulated in lipid nanoparticles that encodes the prefusion-stabilized spike protein of SARS-CoV-2. A Phase II study (NCT04969276) evaluated the safety and immunogenicity of giving these two vaccines during the same visit compared to separate administrations, finding similar immune responses and no safety concerns.
- Brand names
- Fluzone High-Dose QuadrivalentSpikevax
- Other names
- Quadrivalent Inactivated Influenza High DoseCOVID-19 mRNA Vaccine (nucleoside modified)
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on Fluzone High-Dose Quadrivalent + mRNA-1273.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fluzone High-Dose Quadrivalent + mRNA-1273.